Global Exporter & Bulk Supplier of Cytlieva 100mg Injection

🌍 Introduction

Are you in need of a verified and globally compliant exporter for Cytlieva 100mg Injection? At Ernest Oncology (the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd.), we are leaders in the international distribution of high-quality cytotoxic medications. We provide seamless supply chain solutions for Cytarabine 100mg injections to hospitals, hematology clinics, and pharmaceutical wholesalers in the USA, UK, Australia, and South Africa.

🔬 1. Product Overview: Cytlieva 100mg Injection

Cytlieva 100mg Injection contains Cytarabine (also known as Ara-C), a potent antimetabolite that is a cornerstone in the treatment of various hematological malignancies.

• Composition: Cytarabine 100mg (as a sterile solution or lyophilized powder)

• Therapeutic Class: Antineoplastic / Antimetabolite (Pyrimidine Analog)

• Formulation Type: Single-dose vial for intravenous (IV), intrathecal, or subcutaneous administration.

• Storage: Store at controlled room temperature ($15^\circ\text{C}$ to $30^\circ\text{C}$).

⚙️ 2. Mechanism of Action

Cytlieva 100mg works by disrupting the replication cycle of rapidly dividing cancer cells:

• S-Phase Specificity: Cytarabine is an S-phase cell-cycle specific agent. It is converted intracellularly into its active form, Cytarabine triphosphate.

• DNA Polymerase Inhibition: It acts by inhibiting DNA polymerase, an enzyme critical for DNA synthesis.

• DNA Incorporation: The active metabolite is incorporated into the DNA strand, preventing further elongation and leading to cell death (apoptosis).

• Targeted Efficacy: Because it mimics natural pyrimidines, cancer cells "mistake" it for a building block, effectively shutting down the tumor's growth from within.

🏥 3. Therapeutic Indications

Cytlieva 100mg Injection is clinically indicated for:

• Acute Myeloid Leukemia (AML): A primary component of induction and maintenance therapy.

• Acute Lymphocytic Leukemia (ALL): Used in both adult and pediatric treatment protocols.

• Chronic Myeloid Leukemia (CML): Specifically during the blast crisis phase.

• Meningeal Leukemia: Administered intrathecally to treat or prevent the spread of leukemia to the central nervous system.

• Non-Hodgkin’s Lymphoma: Often used in combination regimens for aggressive lymphomas.

⚠️ 4. Administration & Safety Guidelines

• Professional Supervision: Must be administered only by healthcare professionals experienced in cancer chemotherapy.

• Dosage Variance: Dosing varies significantly based on whether the regimen is "Low-Dose," "Standard," or "High-Dose" (HiDAC).

• Hematologic Monitoring: Patients require close monitoring of blood counts due to potential bone marrow suppression.

• Side Effects: Common reactions include nausea, vomiting, mouth sores, and "Cytarabine Syndrome" (fever, rash, and conjunctivitis).

• Special Precaution: Intrathecal administration requires preservative-free formulations.

•